HIGH ASPECT RATIO LAYERED DOUBLE HYDROXIDE MATERIALS AND METHODS FOR PREPARATION THEREOF

Embodiments are directed to adamantane-intercalated layered double-hydroxide (LDH) particles and the methods of producing adamantane-intercalated LDH particles. The adamantane-intercalated LDH particles have a general formula defined by [MAl(OH)](A).mHO, where x is from 0.14 to 0.33, m is from 0.33 to 0.50, M is chosen from Mg, Ca, Co, Ni, Cu, or Zn, and A is adamantane carboxylate. The adamantane-intercalated LDH particles further have an aspect ratio greater than 100. The aspect ratio is defined by the width of an adamantane-intercalated LDH particle divided by the thickness of the adamantane-intercalated LDH particle. 1. An adamantane-intercalated layered double-hydroxide (LDH) material in a form of adamantane-intercalated LDH particles , where the adamantane-intercalated LDH particles comprise:{'sub': 1-x', 'x', '2', 'x', '2, 'a general formula defined by [MAl(OH)](A).mHO, where x is from 0.14 to 0.33, m is from 0.33 to 0.50, M is chosen from Mg, Ca, Co, Ni, Cu, or Zn, and A is adamantane carboxylate; and'}an aspect ratio greater than 100, the aspect ratio defined by a width of an adamantane-intercalated LDH particle divided by a thickness of the adamantane-intercalated LDH particle.2. The adamantane-intercalated LDH material of where M is Mg.3. The adamantane-intercalated LDH material of where the aspect ratio is greater than 125.4. The adamantane-intercalated LDH material of where the aspect ratio is greater than 150.5. The adamantane-intercalated LDH material of where the aspect ratio is greater than 200.6. The adamantane-intercalated LDH material of where the adamantane-intercalated LDH particles have a particle diameter of 5 to 10 μm.7. The adamantane-intercalated LDH material of where the adamantane-intercalated LDH particles have characteristic peaks in an IR spectra at 1517 cm claim 1 , 1395 cm claim 1 , 2901 cm claim 1 , 2847 cm claim 1 , and 4302 cm. This application is a divisional application of U.S. patent application Ser. No. 15/449,207 filed Mar. ...

MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to binary phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions. 136-. (canceled)37. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a co-crystal comprising supramolecular synthons , each supramolecular synthon formed from stoichiometric amounts of at least one active pharmaceutical ingredient (API) and at least one co-former ,wherein the API has a first chemical functionality that permits formation of API homosynthons through non-covalent hydrogen bonding when the API is in its pure form,wherein the co-former has a second chemical functionality complimentary to the first chemical functionality via non-covalent hydrogen bonding,wherein said co-former is a solid at room temperature and atmospheric pressure when the co-former is in its pure form,wherein said co-former is not an API, andwherein supramolecular synthons are formed via non-covalent hydrogen bonding between the first chemical functionality of the API and the second chemical functionality of the co-former.38. The pharmaceutical composition of claim 37 , wherein the supramolecular synthon comprises a supramolecular heterosynthon dimer formed by non-covalent hydrogen bonding of the API to the co-former.39. The pharmaceutical composition of claim 37 , wherein the supramolecular synthon comprises a plurality of the API and a plurality of the co-former claim 37 , wherein the supramolecular synthon is a chain of supramolecular heterosynthons claim 37 , each supramolecular heterosynthon formed by non-covalent hydrogen bonding of one API to one co-former claim 37 , and wherein the supramolecular heterosynthons are bonded to one another by non-covalent hydrogen bonding.40. The pharmaceutical composition of claim 37 , ...

RESIST COMPOSITION AND PATTERNING PROCESS

A resist composition comprising a base polymer and a quencher containing a sulfonium salt having an iodized benzene ring offers a high sensitivity, minimal LWR and improved CDU independent of whether it is of positive or negative tone. 2. The resist composition of wherein m is an integer of 2 to 5.3. The resist composition of claim 1 , further comprising an organic solvent.4. The resist composition of claim 1 , further comprising an acid generator capable of generating a fluorosulfonic acid claim 1 , fluoroimidic acid or fluoromethide acid.5. The resist composition of claim 1 , further comprising a base polymer.7. The resist composition of which is a chemically amplified positive resist composition.8. The resist composition of wherein the base polymer is free of an acid labile group.9. The resist composition of which is a chemically amplified negative resist composition.11. The resist composition of claim 1 , further comprising a surfactant.12. A process for forming a pattern comprising the steps of applying the resist composition of onto a substrate claim 1 , baking to form a resist film claim 1 , exposing the resist film to high-energy radiation claim 1 , and developing the exposed resist film in a developer.13. The process of wherein the high-energy radiation is ArF excimer laser radiation of wavelength 193 nm or KrF excimer laser radiation of wavelength 248 nm.14. The process of wherein the high-energy radiation is EB or EUV of wavelength 3 to 15 nm. This non-provisional application claims priority under 35 U.S.C. § 119(a) on Patent Application No. 2018-173598 filed in Japan on Sep. 18, 2018, the entire contents of which are hereby incorporated by reference.This invention relates to a resist composition and a pattern forming process.To meet the demand for higher integration density and operating speed of LSIs, the effort to reduce the pattern rule is in rapid progress. In particular, the enlargement of the logic memory market to comply with the wide-spread use ...

SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR

This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer. 1. A salt , which is 4 ,4′-(((((2 ,2′-dichloro-[1 ,1′-biphenyl]-3 ,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1 ,4 ,6 ,7-tetrahydro-5H-imidazo[4 ,5-c]pyridine-2 ,5-diyl))bis(ethane-2 ,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid) di-hydrochloric acid salt.2. The salt of claim 1 , having Form I.3. The salt of claim 2 , having an X-ray powder diffraction pattern as substantially shown in .4. The salt of claim 2 , having a DSC thermogram substantially as depicted in .5. The salt of claim 2 , having a thermogravimetric analysis (TGA) thermogram substantially as depicted in .6. The salt of claim 2 , having at least one X-ray powder diffraction (XRPD) peak claim 2 , in terms of 2-theta (±0.2 degrees) claim 2 , selected from 5.7 claim 2 , 8.5 claim 2 , 9.6 claim 2 , 9.9 claim 2 , 11.8 claim 2 , 12.3 claim 2 , 13.1 claim 2 , 13.4 claim 2 , 13.8 claim 2 , 14.2 claim 2 , 14.5 claim 2 , 15.4 claim 2 , 15.8 claim 2 , 16.8 claim 2 , 17.3 and 17.6 degrees.7. The salt of claim 2 , having at least two X-ray powder diffraction (XRPD) peaks claim 2 , in terms of 2-theta (±0.2 degrees) claim 2 , selected from 5.7 claim 2 , 8.5 claim 2 , 9.6 claim 2 , 9.9 claim 2 , 11.8 claim 2 , 12.3 claim 2 , 13.1 claim 2 , 13.4 claim 2 , 13.8 claim 2 , 14.2 claim 2 , 14.5 claim 2 , 15.4 claim 2 , 15.8 claim 2 , 16.8 claim 2 , 17.3 and 17.6 degrees.8. The salt of claim 2 , having at least three X-ray powder diffraction (XRPD) peaks claim 2 , in terms of 2-theta (±0.2 degrees) claim 2 , selected from 5.7 claim 2 , 8.5 claim 2 , ...

Multiple-component solid phases containing at least one active pharmaceutical ingredient

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

Method for preparing 3(4),8(9)-bisformyltricyclo[5.2.1.0^2,6]decane

A method of preparing 3(4),8(9)-bisformyltricyclo[5.2.1.0 2,6 ]decane is provided. According to the present invention, 3(4),8(9)-bisformyltricyclo[5.2.1.0 2,6 ]decane (TCDDA) may be prepared with a high conversion rate and purity without a separate catalyst recovery process.

RESIST COMPOSITION AND PATTERN FORMING PROCESS

A resist composition comprising a quencher containing a sulfonium salt having the formula (A). 2. The resist composition of claim 1 , further comprising an organic solvent.3. The resist composition of claim 1 , further comprising an acid generator capable of generating fluorosulfonic acid claim 1 , fluoroimidic acid claim 1 , or fluoromethide acid.4. The resist composition of claim 1 , further comprising a base polymer.6. The resist composition of which is a chemically amplified positive resist composition.7. The resist composition of claim 4 , wherein the base polymer is free of an acid labile group.8. The resist composition of which is a chemically amplified negative resist composition.10. The resist composition of claim 1 , further comprising a surfactant.11. A pattern forming process comprising the steps of applying the resist composition of to form a resist film on a substrate claim 1 , exposing the resist film to high-energy radiation claim 1 , and developing the exposed resist film in a developer.12. The pattern forming process of claim 11 , wherein the high-energy radiation is ArF excimer laser radiation of wavelength 193 nm or KrF excimer laser radiation of wavelength 248 nm.13. The pattern forming process of claim 11 , wherein the high-energy radiation is electron beam or extreme ultraviolet of wavelength 3 to 15 nm. This non-provisional application claims priority under 35 U.S.C. § 119(a) on Patent Application No. 2020-031900 filed in Japan on Feb. 27, 2020, the entire contents of which are hereby incorporated by reference.This invention relates to a resist composition and a pattern forming process.As integration density and operating speed of LSIs become higher, the effort to make the pattern rule finer is in rapid progress. In particular, the enlargement of the logic memory market to comply with the wide-spread use of smartphones drives forward the miniaturization technology. As the advanced miniaturization technology, manufacturing of microelectronic ...

Synthesis of transition-metal adamantane salts and oxide nanocomposites, and systems and methods including the salts or the nanocomposites

A method for preparing a transition-metal adamantane carboxylate salt is presented. The method includes mixing a transition-metal hydroxide and a diamondoid compound having at least one carboxylic acid moiety to form a reactant mixture, where M is a transition metal. Further, the method includes hydrothermally treating the reactant mixture at a reaction temperature for a reaction time to form the transition-metal adamantane carboxylate salt.

Synthesis of magnesium adamantane salts and magnesium oxide nanocomposites, and systems and methods including the salts or the nanocomposites

A method for preparing a magnesium adamantane carboxylate salt is provided. The method includes mixing a magnesium salt and a diamondoid compound having at least one carboxylic acid moiety to form a reactant mixture and hydrothermally treating the reactant mixture at a reaction temperature for a reaction time to form the magnesium adamantane carboxylate salt.

HIGH ASPECT RATIO LAYERED DOUBLE HYDROXIDE MATERIALS AND METHODS FOR PREPARATION THEREOF

Embodiments are directed to adamantane-intercalated layered double-hydroxide (LDH) particles and the methods of producing adamantane-intercalated LDH particles. The method comprises adding to an aqueous solution a first precursor and a second precursor to form an initial mixture, where the first precursor is Al(OH)or AlO, the second precursor is a hydroxide M(OH)or an oxide MO, where M is a metal of oxidation state +2; and the initial mixture has a M/Al molar ratio of from 1 to 5. The method also comprises adding to the initial mixture an amount of adamantane to form a reaction mixture having an Al/adamantane molar ratio of from 0.5 to 2; and heating the reaction mixture to produce adamantane-intercalated LDH particles, where the adamantane-intercalated LDH particles have aspect ratios greater than 100.

Multiple-component solid phases containing at least one active pharmaceutical ingredient

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

Unsaturated polyester resin composition

Molecule clathrate compound and the preparation method and application thereof

本发明属于超分子材料技术领域，尤其是涉及一类分子笼化合物及其制备方法与应用。本发明的分子笼化合物可以显著改善笼状化合物在有机溶剂甚至水中的溶解性；本发明的分子笼化合物具有和金刚烷及其衍生物相匹配的空间尺寸，可以为某些不稳定的金刚烷衍生物提供一个封闭性空间，提高其化学稳定性；本发明的分子笼化合物能够选择性的络合金刚烷及其衍生物，同时在特定条件下可以定量释放，并且实现对主体分子的高效回收，这在药物的传输和释放领域具有很大的应用前景。

Synthesis of magnesium adamantane carboxylate and oxide nanocomposite

마그네슘 아다만탄 카복실레이트염의 제조 방법이 제공된다. 상기 방법은 적어도 1종의 카복실산 모이어티를 갖는 다이아몬드형 화합물과 마그네슘염을 혼합하여 반응물 혼합물을 형성시키는 단계 및 반응 온도에서 반응 시간 동안 상기 반응물 혼합물을 열수 처리하여 마그네슘 아다만탄 카복실레이트염을 형성시키는 단계를 포함한다.

Tricycloundecane derivatives

Adamantyl-s-triazines

Chemically-amplified positive resist composition and resist patterning process using the same

An object of the present invention is to provide a chemically amplified positive resist composition using a sulfonium salt having a very high resolution and capable of imparting a small pattern of line edge roughness and a method of forming a resist pattern using the chemically amplified positive resist composition. (A) a salt represented by the following formula (1), (B) a resin which is decomposed by the action of an acid containing a repeating unit represented by the following formula (U-1) and whose solubility in an alkali developer is increased And a resist pattern forming method using the chemically amplified positive resist composition.

Method for preparing 3(4),8(9)-bisformyltricyclo[5.2.1.02,6]decane

The present invention relates to a method for preparing 3(4),8(9)-bisformyltricyclo[5.2.1.0 2,6 ]decane. According to the present invention, a separate catalyst recovery process is not required, and 3(4),8(9)-bisformyltricyclo[5.2.1.0 2,6 ]decane (TCDDA) having a high conversion rate and purity can be prepared.

Patent FR6596M

PROCESS FOR PRODUCING 4-HOMOISOTWISTANE-3-CARBOXYLIC ACID

Patent JPH0226617B2

Patent FR2395247B1

New dicarboxy-adamantanes and their manufacturing process

Patent FR8413M

ADAMANTANE DERIVATIVES AND THEIR APPLICATION

PROCESS FOR THE PRODUCTION OF TRICYCLO (5.2.1.02,6) DECANE-2-CARBOXYLIC ACID

PROCEDE DE PRODUCTION DE L'ACIDE TRICYCLO 5.2.1.0 DECANE-2-CARBOXYLIQUE. POUR OBTENIR L'ACIDE TRICYCLO 5.2.1.0 DECANE-2-CARBOXYLIQUE, ON MET EN CONTACT LE TRICYCLO 5.2.1.0 DEC-8-YL FORMATE (II) AVEC UN CATALYSEUR MINERAL DE CARACTERE FORTEMENT ACIDE. (CF DESSIN DANS BOPI) LES DERIVES ESTERS ET ALCOOLS DE CET ACIDE SONT DES PARFUMS. PROCESS FOR THE PRODUCTION OF TRICYCLO 5.2.1.0 DECANE-2-CARBOXYLIC ACID. TO OBTAIN TRICYCLO 5.2.1.0 DECANE-2-CARBOXYLIC ACID, THE TRICYCLO 5.2.1.0 DEC-8-YL FORMATE (II) IS IN CONTACT WITH A MINERAL CATALYST OF STRONG ACID CHARACTER. (CF DRAWING IN BOPI) ESTERS AND ALCOHOLS DERIVATIVES OF THIS ACID ARE PERFUMES.

Process for the preparation of steroid analogues

TRICYCLO ACID (4.3.1.1 2,5) UNDECANE-1-CARBOXYLIC, ITS DERIVATIVES AND THEIR PREPARATION PROCESS

a. Acide tricyclo Ø4.3.1.1 ** 2,5õ undécane-1-carboxylique, ses dérivés et leur procédé de préparation. b. Ces composés répondent à la formule : at. Tricyclo acid Ø4.3.1.1 ** 2,5õ undecane-1-carboxylic, its derivatives and process for their preparation. b. These compounds correspond to the formula:

Process for the production of adamantane-carboxaldehydes and intermediate products obtained in the implementation of this process

Salts and crystalline forms of a pd-1/pd-l1 inhibitor

This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.

Magnesium adamantane carboxylate and magnesium oxide nanocomposite

Adamantylamino-tetrahydronaphthyl-oxypropanols and ester derivatives

CH(-R4)-N(-R3)-(CH2)M-)ADAMANTANE AND TO SALTS OF SUCH COMPOUNDS, PRODUCTS WHICH ARE USEFUL IN CORONARY DISEASES AND AS ANTIVIRAL AGENTS. THIS INVENTION RELATES TO NEW ADAMANTYLAMINO-5,6,7,8,TETRAHYDRONAPHTHYLOXYPROPANOLS AND RELATED COMPOUNDS OF THE FORMULA 3-R1,5-R2,7-((TETRAHYDRONAPHTHYL)-O-C(-R5)(-R6)-CH(-O-R7)-

Resist composition, method of forming resist pattern, acid generator, photoreactive quencher, and compound

A resist composition which generates acid upon exposure and exhibits changed solubility in a developing solution under action of acid, and which includes a base component which exhibits changed solubility in a developing solution under action of acid and an acid-generator component including a compound (B0-1) represented by general formula (b0) shown below in which Ra 1 represents an aromatic ring; Ra 01 represents an alkyl group of 5 or more carbon atoms optionally having a substituent; Ra 02 and Ra 03 each independently represents an alkyl group of 1 to 10 carbon atoms optionally having a substituent; n1 represents an integer of 1 to 5; n2 represents an integer of 0 to 2; n3 represents an integer of 0 to 4; and X − represents a counteranion.

Multi-component solid phase containing at least one active pharmaceutical ingredient

Deuterium-enriched composition, deuterium-substituted carboxylic acid production method, reaction accelerator, and use of compound for converting carboxylic acid to acid anhydride

Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the α hydrogen bonded to a carbon, the deuterium substitution rate of the α hydrogen is not less than 5%, the deuterium substitution rate of the hydrogen other than the α hydrogen is not more than 3%, and when the carboxylic acid or the salt thereof comprises, in the molecule thereof, a group having a carbonyl group other than the carboxy group, the α hydrogen of the carbonyl group is not included in hydrogen other than the α hydrogen.

Photoresist composition

The present invention A resin which contains a structural unit derived from a compound having an acid labile group and is insoluble or hardly soluble in an aqueous alkali solution but becomes soluble in an aqueous alkaline solution by the action of an acid, Acid generator, and A compound represented by the formula (I ') shown below A photoresist composition comprising: Wherein each of R 51 , R 52 , R 53 and R 54 independently represents a C 1 -C 8 alkyl group, A 11 may contain at least one hetero atom, and may contain C3-C36 2 Represents a saturated cyclic hydrocarbon group or a C6-C20 divalent aromatic hydrocarbon group which may contain at least one hetero atom and which has at least one substituent.

High aspect ratio layered double-hydroxide material and preparation method

实施例涉及插入有金刚烷的层状双氢氧化物(LDH)颗粒和制备插入有金刚烷的LDH颗粒的方法。所述方法包含向水溶液中加入第一前体和第二前体以形成初始混合物，其中所述第一前体是Al(OH) 3 或Al 2 O 3 ，所述第二前体是氢氧化物M(OH) 2 或氧化物MO，其中M是氧化态为+2的金属；且所述初始混合物的M/Al摩尔比为从1至5。所述方法还包含向所述初始混合物中加入一定量的金刚烷以形成Al/金刚烷摩尔比为从0.5至2的反应混合物；和加热所述反应混合物以制备插入有金刚烷的LDH颗粒，其中所述插入有金刚烷的LDH颗粒具有大于100的纵横比。

New Adamantylidene Compounds

Patent FR1604063A

1-(1-Aminoalkyl)tricyclo[4,3,1,12,5 ]undecanes

Compounds having the formula ##STR1## in which R is lower alkyl, and acid addition salts of said compounds. The compounds possess anti-RNA-viral activity and also an antiviral activity against herpes virus.

FRAGRANCE COMPOSITION BASED ON TRICYCLO (5.2.1.0.2.6) METHYL DECANE-2-CARBOXYLATE AND PROCESS FOR PREPARING THE SAME

NOUVELLE COMPOSITION DE PARFUM. ELLE CONTIENT LE COMPOSE DE FORMULE: (CF DESSIN DANS BOPI) PARFUMERIE. NEW PERFUME COMPOSITION. IT CONTAINS THE COMPOUND OF FORMULA: (CF DRAWING IN BOPI) PERFUMERY.

Process for preparing adamantylamino-naphthyloxy-propanols

High aspect ratio layered double hydroxide materials and methods for preparation thereof

Method of producing adamantane-intercalated LDH particles (i) [preferably Ad-COOH; Mg/AI-LDH] comprising adding to an aqueous solution a first precursor, AI(OH)3, and a second precursor, a hydroxide M(OH)2 or an oxide MO [preferably M= Mg, Ca, Co, Ni, Cu, Zn], to form an initial mixture, the initial mixture having an M/ Al molar ratio of from 1 to 5, adding to the initial mixture an amount of adamantane [preferably Ad-COOH] to form a reaction mixture having an Al/adamantane molar ratio of from 0.5 to 2, and heating the reaction mixture to produce (i), having an aspect ratio, i.e. width/thickness of particles, of greater than 100.

NOVEL ESTERS OF TRICYCLO ACID (5.2.1.02,6) DECANE-2-CARBOXYLIC, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN PERFUMERY

NOVEL ESTERS OF TRICYCLO (5.2.1.02,6) DECANE-2-CARBOXYLIC ACID, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN PERFUMERY

NOUVEAUX ESTERS D'ACIDES CARBOXYLIQUES TRICYCLIQUES. ILS REPONDENT A LA FORMULE: (CF DESSIN DANS BOPI) DANS LAQUELLE R EST UN RADICAL ALKYLE COMPORTANT 2 OU 3ATOMES DE CARBONE. CES ESTERS QUI POSSEDENT UNE ODEUR AGREABLE SONT UTILISES DANS LA PREPARATION DE DIVERS PRODUITS PARFUMES, TELS QUE DETERGENTS ET COSMETIQUES, NOTAMMENT SHAMPOOINGS ET SAVONS.

High aspect ratio layered double hydroxide materials and methods for preparation thereof

High aspect ratio layered double hydroxide material and its preparation method

Salts and crystalline forms of a pd-1/pd-l1 inhibitor

This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.

Tricyclodecane monomethanol monocarboxylic acid and derivatives thereof

Provided are a novel tricyclodecane monomethanol monocarboxylic acid and derivatives thereof which can be employed as starting materials for highly heat-resistant alicyclic polyester or the like. The tricyclodecane monomethanol monocarboxylic acid is represented by general formula (I), and derivatives thereof are also provided. (I)

High aspect ratio layered double hydroxide materials and methods for preparation thereof

Method of producing adamantane-intercalated LDH particles (i) [preferably Ad-COOH; Mg/AI-LDH] comprising adding to an aqueous solution a first precursor, AI(OH)3, and a second precursor, a hydroxide M(OH)2 or an oxide MO [preferably M= Mg, Ca, Co, Ni, Cu, Zn], to form an initial mixture, the initial mixture having an M/ Al molar ratio of from 1 to 5, adding to the initial mixture an amount of adamantane [preferably Ad-COOH] to form a reaction mixture having an Al/adamantane molar ratio of from 0.5 to 2, and heating the reaction mixture to produce (i), having an aspect ratio, i.e. width/thickness of particles, of greater than 100.

Patent JPH0153663B2

Preparation of dicarboxy adamantane compounds

Compounds of formula 1,3-A(CO2H)2 where there is an adamantane nucleus optionally substituted by up to 2 alkyl groups which contain a total of 1-10 C atoms, are prepared by dissolving (i) A(OH)2 in 96-104 wt. per cent H2SO4, or (ii) ABr2 or ACl2 in 100-110 wt. per cent H2SO4, the molar ratio of H2SO4 to A(OH)2, ABr2 o ACl2 being at least 10:1, reacting the mixture with at least 2 moles HCO2H per mole A(OH)2, ABr2 or ACl2, mixing with water and separating the product.

1-Aminomethyl-tri:cycloundecane - useful as antiviral agent esp. against Newcastle disease virus

Adamantyl-s-triazines antimicrobials hypoglycaemics

Patent FR2020826A1

Adamantylaminophenoxypropanols

Resist composition, method of forming resist pattern, acid generator, photoreactive quencher, and compound

一種阻劑組成物，其為經由曝光而產生酸，經由酸的作用而使對顯影液之溶解性產生變化之阻劑組成物，其特徵為，含有經由酸的作用而使對顯影液之溶解性產生變化之基材成份(A)，與經由曝光而產生酸之酸產生劑成份(B)，前述酸產生劑成份(B)為含有下述通式(b0)所表示之化合物(B0-1)。 □ [式中，Ra1表示芳香環，Ra01為可具有取代基之碳數5以上之烷基，Ra02、Ra03，各自獨立為可具有取代基之碳數 1~10之烷基。n1為1~5之整數，n2為0~2之整數，n3為0~4之整數。X-為對陰離子]。

2*44exoo etanobishikuro * 3*3*1 * nonanno seizoho

Tricyclodecane monomethanol monocarboxylic acid and derivatives thereof

本发明提供一种能够成为高耐热脂环式聚酯等的原料的新型三环癸烷单甲醇单羧酸及其衍生物。由下述通式(I)表示的三环癸烷单甲醇单羧酸及其衍生物。

Preparation of dicarboxyadamantane coumpounds

Multiple-component solid phases containing at least one active pharmaceutical ingredient

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

Synthesis of transition metal adamantane carboxylate salt and oxide nanocomposite

전이금속 아다만탄 카복실레이트염의 제조 방법이 제공된다. 상기 방법은 전이금속 수산화물 및 적어도 하나의 카복실산 모이어티를 갖는 다이아몬도이드 화합물을 혼합하여 반응물 혼합물을 형성하는 단계 (여기서 M은 전이금속임)를 포함한다. 또한, 상기 방법은 반응 시간 동안 반응 온도에서 반응물 혼합물을 열수 처리하여 전이금속 아다만탄 카복실레이트염을 형성하는 단계를 포함한다. A method for preparing a transition metal adamantane carboxylate salt is provided. The method includes mixing a transition metal hydroxide and a diamondoid compound having at least one carboxylic acid moiety to form a reactant mixture, where M is a transition metal. Further, the method includes the step of hydrothermally treating the reactant mixture at a reaction temperature during the reaction time to form a transition metal adamantane carboxylate salt.

Multiple-component solid phases containing at least one active pharmaceutical ingredient

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

Adamantyl-s-triazines antimicrobials hypoglycaemics

Cpds. (I) and acid addn. salts: R, Ro = H, halogen, alkyl, alkoxy, Ph or phenyl alkyl R' = H or alkyl R2 = H, alkyl or halo-alkyl R3, R4 = H, alkyl or phenyl-alkyl n = 0, 1 or 2. Antimicrobials (e.g. antivirals against influenza virus such as A-PR8 or hepatic virus such as MHV3, or antibacterials against e.g. Staphylococci or Diplococci) and oral hypoglycaemics.

Patent FR2017657B1

Multiple-component solid phases containing at least one active pharmaceutical ingredient

Patent FR2100944A1

Salts and crystalline forms of a pd-1/pd-l1 inhibitor

La presente solicitud se relaciona con formas sólidas y formas de sal del inhibidor de PD-1/PD-L1 4,4'-(((((2,2'-dicloro-[1,1'-bifenil]-3,3'-diil)bis(azanodiil))bis(carbonil))bis(1-metil-1,4,6,7-tetrahidro5 5H-imidazo[4,5-c]piridina-2,5-diil))bis(etano-2,1-diil))bis(biciclo[2.2.1]heptano-1-ácido carboxílico), que incluye procesos de preparación de estas, donde las formas sólidas y las formas en sal son útiles para el tratamiento de diversas enfermedades que incluyen enfermedades infecciosas y cáncer

Spirocyclopropyl amides and acids and their therapeutic applications

The present invention relates to the use of compounds of Formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection.

Patent FR2020824B1

Tricyclodecane monomethanol monocarboxylic acid and its derivatives

高耐熱脂環式ポリエステル等の原料となり得る新規なトリシクロデカンモノメタノールモノカルボン酸及びその誘導体を提供する。下記一般式（Ｉ）で表されるトリシクロデカンモノメタノールモノカルボン酸及びその誘導体。 Provided are novel tricyclodecane monomethanol monocarboxylic acid and derivatives thereof which can be a raw material for highly heat-resistant alicyclic polyester and the like. Tricyclodecane monomethanol monocarboxylic acid represented by the following general formula (I) and derivatives thereof.

Tricyclo[6.4.0.02,7 ]-dodecane-1,8,2,7-tetracarboxylic acid dianhydride and polyimides therefrom

Novel polyimides and molding compositions are prepared from tricyclo[6.4.0.0 2 ,7 ]dodecane-1,8,2,7-tetracarboxylic acid dianhydride. Also a novel dianhydride-,tricyclo[6.4.0.0 2 ,7 ]dodecane-1,8,2,7-tetracarboxylic acid dianhydride is prepared by a novel photodimerization of 1-cyclohexene-1,2-dicarboxylic anhydride. The polyimides are useful as engineering plastics.

Spirocyclopropyl amides and acids and their therapeutic applications

The present invention relates to the use of compounds of Formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection.

Photoresist composition

本发明提供一种光刻胶组合物，包含：树脂，其含有衍生自具有酸敏基团的化合物的结构单元，且其不溶或难溶于碱性水溶液但在酸的作用下变得可溶于碱性水溶液，产酸剂，和式(I′)表示的化合物：其中R 51 、R 52 、R 53 和R 54 各自独立地代表C1-C8烷基，A 11 代表可含有1个或更多个杂原子且具有1个或更多个取代基的C3-C36二价饱和环烃基，或者可含有1个或更多个杂原子且具有1个或更多个取代基的C6-C20二价芳烃基。

Multiple-component solid phases containing at least one active pharmaceutical ingredient

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

Patent DE3325983C2

Procédé de préparation d'adamantyl-lactames

３（４），８（９）—雙甲醯基三環［５‧２‧１‧０^２，６］癸烷的製備方法

提供了一種3(4),8(9)-雙甲醯基三環[5.2.1.0 2,6 ]癸烷的製備方法。根據本發明，3(4),8(9)-雙甲醯基三環[5.2.1.0 2,6 ]癸烷(TCDDA)可以高轉化率和高純度製備，且無需額外的催化劑回收製程。

3(4),8(9)-雙甲醯基三環[5.2.1.0^2,6]癸烷的製備方法

提供了一種3(4),8(9)-雙甲醯基三環[5.2.1.0 2,6 ]癸烷的製備方法。根據本發明，3(4),8(9)-雙甲醯基三環[5.2.1.0 2,6 ]癸烷(TCDDA)可以高轉化率和高純度製備，且無需額外的催化劑回收製程。

Salts and crystalline forms of a PD-1/PD-L1 inhibitor

This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.

Sales y formas cristalinas de un inhibidor de pd-1/pd-l1

La presente solicitud se relaciona con formas sólidas y formas de sal del inhibidor de PD-1/PD-L1 4,4'- (((((2,2'-dicloro-(1,1'-bifenil)-3,3'-diil)bis(azanodiil)bis(carbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo(4,5-c)piridina-2,5-diil))bis(etano-2,1-diil))bis(biciclo(2.2.1)heptano-1-ácido carboxílico),que incluye procesos de preparación de estas, donde las formas sólidas y las formas en sal son útiles para el tratamiento de diversas enfermedades que incluyen enfermedades infecciosas y cáncer.

3(4),8(9)-双甲酰基三环[5.2.1.02,6]癸烷的制备方法

提供了一种制备3(4),8(9)‑双甲酰基三环[5.2.1.0 2,6 ]癸烷的方法。根据本发明，3(4),8(9)‑双甲酰基三环[5.2.1.0 2,6 ]癸烷(TCDDA)可以在没有单独的催化剂回收工艺的情况下以高的转化率和纯度制备。

Verfahren zur herstellung des neuen octahydro-1,2,4-methenopentalenyl-(5)-amins und dessen salzen

Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).

La presente solicitud se relaciona con formas sólidas y formas de sal del inhibidor de PD-1/PD-L1 4,4'-(((((2,2'-dicloro-[1,1'-bifen il]-3,3'-diil)bis(azanodiil))bis(carbonil))bis(1-metil-1,4,6,7-te trahidro-5H-imidazo[4,5-c]piridina-2,5-diil))bis(etano-2,1-diil)) bis(biciclo[2.2.1]heptano-1-ácido carboxílico), que incluye procesos de preparación de estas, donde las formas sólidas y las formas en sal son útiles para el tratamiento de diversas enfermedades que incluyen enfermedades infecciosas y cáncer.

Fusionierte cycloalkyl amid- und carbonsäure- derivate und deren therapeutische verwendung zur behandlung von u.a. epilepsie

抗蚀剂组合物和图案化方法

本发明为抗蚀剂组合物和图案化方法。包含基础聚合物和含有具有碘化的苯环的锍盐的猝灭剂的抗蚀剂组合物提供高感光度、最小的LWR和改进的CDU，而不管其为正色调的还是负色调的。

レジスト材料及びパターン形成方法

Sales y formas cristalinas de un inhibidor de pd-1/pd-l1

Referido a una sal de acido diclorhidrico de 4,4'-(((((2,2'-dicloro-[1,1'-bifenil]-3,3'- diil)bis(azanediil))bis(carbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciclo[2.2.1]heptan-1-acido carboxilico) y sus formas cristalinas. En donde dicha sal tiene al menos un pico de difraccion de rayos X en polvo (XRPD), en terminos de 2-theta ( 0.2 grados), seleccionado de 5.7, 8.5, 9.6, 9.9, entre otros. Este compuesto es un inhibidor DE PD-1/PD-L1. Tambien se refiere a una composicion farmaceutica que comprende dicha sal, una forma de dosificacion oral solida, un proceso para la preparacion de dicha sal.

[UNK]

[UNK]

Adamantyllactame und Verfahren zu ihrer Herstellung

[UNK]

Spirocyclopropyl-amide und -säuren und ihre therapeutischen anwendungen

Salts and crystalline forms of a pd-1/pd-l1 inhibitor

This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.

섬 오갈피 성분으로부터 제조되는 신규 화합물 및 그 제조방법

본 발명은 섬 오갈피 나무의 근피 및 수피의 추출물에서 단리된 디테르펜 성분 또는 그 유도체로부터 합성된 신규 화합물과 그 제조 방법에 관한 것이다. 본 발명은 뛰어난 항염증 작용을 가지는 다음 구조식(Ⅰ)의 신규의 디테르펜 유도체에 관한 것이다. 본 발명은 또한 섬 오갈피 나무의 근피 및 수피로부터 추출된 순수 디테르펜계 화합물 중 다음 구조식(Ⅱ)의 (-)-피라마-9(11),15-디엔-4-카복실산 ((-)-pimara-9(11),15-diene-4-carboxylic acid) 유도체를 환원시키거나 에폭시화 시켜, 또는 생성된 모노에폭사이드 화합물을 환원시켜 다음 구조식(Ⅰ)의 디테르펜 유도체를 제조하는 방법에 관한 것이다. 상기 식에서, R은 수소, 메틸 또는 에틸기이고, R′는 에틸, 비닐, 또는 에폭시기이며, n은 0 또는 1이다. 추출물로부터 단리된 단일 순수활성성분 및 그로부터 합성된 본 발명의 유도체들은 염증 치료 및 진통 효과에 유용한 것으로 판명되었다.

光阻材料及圖案形成方法

本發明之課題係提供於正型光阻材料、負型光阻材料皆為高感度且LWR、CDU小之光阻材料、及使用該光阻材料之圖案形成方法。一種光阻材料，含有包含下式(1)表示之鋶鹽的淬滅劑。

8-烷基-8-三环癸基5-降冰片烯-2-羧酸酯及其制备方法

本发明提供了一种降冰片烯羧酸酯化合物及其制备方法。该降冰片烯羧酸酯化合物为分子式(1)所示的8-烷基-8-三环癸基5-降冰片烯-2-羧酸酯，其中R为甲基或乙基。

2-烷基-2-金刚烷基5-降冰片烯-2-羧酸酯及其制备方法

本发明提供了一种新型降冰片烯羧酸酯化合物及其生产方法。降冰片烯羧酸酯化合物为分子式(1)所示的2-烷基-2-金刚烷基5-降冰片烯-2-羧酸酯，其中R为甲基或乙基。

Fused cycloalkyl amides and acids and their therapeutic applications for the treatment of i.a. epilepsy

The present invention relates to the use of compounds of formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection.

Fusionierte cycloalkyl amid- und carbonsäure-derivate und deren therapeutische verwendung zur behandlung von u.a. epilepsie